Direct compression lines manufacturing buflomedil hydrochloride oral tablets at a nominal dose of 150 mg per unit require that the API be pre-sieved through a 500 µm stainless-steel sieve and dry-blended with microcrystalline cellulose, lactose monohydrate and crospovidone in a 600 L bin blender at 10 rpm for 20 min; magnesium stearate is then charged through a separate 500 µm screen and blended for an additional 2 min at 15 rpm to limit shear-induced overlubrication. The API addition ratio is derived from the uncoated core mass: for a 350 mg core carrying 150 mg buflomedil hydrochloride, the active fraction is 42.9% w/w, and the workable range across tooling sizes is 40–50% w/w when the core mass shifts from 300 mg to 375 mg. This high active fraction keeps the tablet sufficiently small for palatability while retaining enough excipient volume for compaction. Compression is performed on a rotary press with precompression at 4–6 kN and main compression at 12–18 kN; tablet hardness is checked at 60–90 N and friability is maintained below 0.8% after 100 rotations according to Ph. Eur. 2.9.7. Blend uniformity is evaluated before compression using a sampling plan of 10 stratified locations, and the acceptance criterion for buflomedil hydrochloride content is 95–105% of label claim with an RSD not exceeding 5.0%. In-process sampling follows FDA 21 CFR 211.110, and finished dosage uniformity is verified against Ph. Eur. 2.9.40 with an acceptance value not exceeding 15. Dissolution is evaluated using Ph. Eur. 2.9.3 with apparatus 2 at 50 rpm in 900 mL of 0.1 M hydrochloric acid at 37 ± 0.5 °C; residual solvent and elemental impurity control follow ICH Q3C and ICH Q3D. At relative humidity above 60%, ribbon sticking or picking on the punch faces becomes more frequent, so the compression zone air is dehumidified to 40–50% RH. The terminal product is a film-coated immediate-release tablet in 150 mg or 300 mg strength, packed in PVC/PVDC/aluminium blisters with cold-form foil for moisture-sensitive markets.

What Limits High-Shear Wet Granulation for a Water-Soluble Hydrochloride Salt?

High-shear wet granulation is employed when a tablet formulation must achieve higher mechanical strength for high-speed blister packaging, but the water-soluble hydrochloride salt introduces a narrow wet-mass endpoint window and a risk of uncontrolled agglomeration if liquid addition rate is not tightly controlled. The API is dry-mixed with lactose monohydrate, microcrystalline cellulose and povidone K30 binder at an addition ratio of 33.3% w/w active drug when a 150 mg dose is embedded in a 450 mg granulated core; the remainder is composed of filler, binder, disintegrant and lubricant. Granulation is performed in a top-drive high-shear granulator with impeller speed 200–300 rpm and chopper speed 1500–1800 rpm; purified water is sprayed at 10–15 g/min per kg of dry blend, and the process is stopped when wet mass loss-on-drying reaches 1.5–2.5%. The wet mass is discharged through a 1.0 mm sieve and dried in a fluid-bed dryer with inlet air at 50–60 °C until residual moisture is not more than 2.0%. Dried granules are milled through a 0.8 mm screen and blended with crospovidone and magnesium stearate; magnesium stearate is limited to 3 min final blending because hydrophobic lubricant films on granule surfaces can delay dissolution. Disintegration is tested according to Ph. Eur. 2.9.1 with a limit of not more than 15 min in 0.1 M hydrochloric acid, and uniformity of dosage units according to Ph. Eur. 2.9.40. Residual solvent levels are managed under ICH Q3C if ethanol or isopropyl alcohol is introduced during granulation, and residual moisture after drying is controlled under the finished product specification. The terminal product is a film-coated immediate-release tablet with reduced friability and higher tensile strength for automated packaging; this route is selected when direct compression cannot meet the target hardness at the required turret speed. The granule route also permits a lower active fraction than direct compression, which reduces the impact of API particle size variability on content uniformity.

Hard gelatin capsule filling requires a dry, free-flowing powder blend with a bulk density in the range 0.45–0.60 g/mL and a particle size distribution where D90 is controlled below 250 µm to avoid fill weight fluctuation on dosator-type machines. The API addition ratio for a size 0 capsule is commonly 42.9–46.9% w/w, corresponding to a 150 mg active charge inside a total fill mass of 320–350 mg; the exact ratio is determined by the API assay and the acceptable fill weight tolerance of ± 5% during process validation. The API is passivated through a 500 µm sieve and blended with lactose monohydrate, croscarmellose sodium and colloidal silicon dioxide in a V-blender at 25 rpm for 18 min; sodium stearyl fumarate is then added at 0.5–1.0% w/w and blended for 3 min to reduce ejection and capsule-opening defects. Encapsulation is performed on a dosator capsule filling machine with pin setting 3 mm and powder bed depth 18–22 mm; in-process fill weight is checked at intervals not exceeding 15 min per FDA 21 CFR 211.110. Disintegration is tested according to Ph. Eur. 2.9.1, and the capsule shell must show rupture within 15 min in 0.1 M hydrochloric acid at 37 ± 0.5 °C; content uniformity follows Ph. Eur. 2.9.40. If ambient relative humidity exceeds 60%, the API is pre-dried in a tray dryer at 40–45 °C until moisture is below 1.0%, because moisture gain above this threshold can cause powder bridging in the hopper and fill weight fluctuation during long encapsulation campaigns. Elemental impurity testing follows ICH Q3D; the capsule shell supplier must furnish a Type III drug master file documenting gelatin or hypromellose composition and absence of animal-derived components where specified by the marketing authorization. The terminal product is a hard gelatin or hydroxypropyl methylcellulose capsule containing 150 mg buflomedil hydrochloride for oral administration.

Oral Granule Sachet Manufacturing and Humidity-Sensitive Blending Parameters

For single-dose oral granule sachets, buflomedil hydrochloride is dispersed in a water-soluble matrix of mannitol, xylitol, citric acid and a binder such as povidone or hydroxypropyl cellulose; the API addition ratio is typically 7.5–12.5% w/w, calculated from a 150 mg active dose distributed into a 1.2–2.0 g finished granule mass. The granulation process is executed in a fluid-bed granulator with inlet air at 50–60 °C, spray rate 15–25 g/min per kg, and product temperature held at 28–34 °C; granulation is stopped when the moisture content reaches 2.0–3.0%, and the dried granules are sieved to a particle size range of 0.5–1.25 mm. The granule size distribution is a critical parameter because excessively fine granules below 0.25 mm segregate in the sachet filler hopper, while granules above 1.4 mm obstruct the auger dosing tube and cause weight variation. Sachet filling is conducted in an environment below 45% RH to prevent hygroscopic mannitol surfaces from becoming sticky; finished sachets are sealed in aluminium-laminated film with a moisture vapour transmission rate below 0.5 g/m²/day to maintain stability. Dissolution testing follows Ph. Eur. 2.9.3, with the granule dose added to 900 mL of dissolution medium at 37 °C, and uniformity of mass of delivered doses follows Ph. Eur. 2.9.40. Elemental impurities are controlled under ICH Q3D, and residual solvents under ICH Q3C if non-aqueous granulation solvents are introduced. The terminal product is a single-dose oral granule sachet reconstituted in water before ingestion, aimed at patients with dysphagia or those requiring dose adjustment in divided administration. Published data for this specific configuration is limited, so the dissolution specification and water content limit must be established through design of experiments rather than transferred directly from tablet monographs.

If Terminal Sterilization Is Applied to an Aqueous Buflomedil HCl Solution

When an aqueous buflomedil hydrochloride injection is prepared at a concentration of 10–20 mg/mL, equivalent to 1.0–2.0% w/v, the selection of terminal sterilization instead of aseptic filtration depends on the thermal degradation profile of the API in the chosen pH environment. The solution is compounded in Water for Injections at 20–25 °C, adjusted with 0.1 M hydrochloric acid or 0.1 M sodium hydroxide to a pH below 7.0 to maintain the hydrochloride salt in solution and avoid free-base precipitation, then sparged with purified nitrogen to reduce dissolved oxygen below 0.5 mg/L. The bulk solution is filtered through 0.22 µm polyethersulfone membrane filters and transferred under pressure into a filling line that delivers 5 mL or 10 mL portions into amber type I glass ampoules under Grade A unidirectional airflow with Grade B background. If terminal sterilization is pursued, a validated cycle achieving an F0 of at least 8 at 121 °C for 15 min is applied using superheated water spray or steam-air mixture autoclaves; if forced degradation studies demonstrate that this thermal load increases any unknown impurity above the ICH Q3B identification threshold, the process is switched to aseptic filtration without terminal heat. Sterility is tested according to Ph. Eur. 2.6.1, bacterial endotoxins according to Ph. Eur. 2.6.14 or USP <85>, and sub-visible particulate matter according to Ph. Eur. 2.9.19 or USP <788>. Visible particulates are inspected under Ph. Eur. 2.9.20 or USP <790> with reject limits for black specks and fibre-shaped particles. The terminal product is a single-dose glass ampoule containing 100 mg/5 mL or 200 mg/10 mL buflomedil hydrochloride for intravenous administration after dilution; container-closure integrity is verified by vacuum decay or dye ingress under EU GMP Annex 1.

For large-volume parenteral infusion, the ampoule solution is diluted at the point of care or in a centralized admixture service into 250–500 mL infusion bags containing 0.9% sodium chloride or 5% glucose; the final drug concentration is typically 0.2–0.4 mg/mL when 100–200 mg is added to 500 mL, corresponding to 0.02–0.04% w/v. The infusion container must be free of di(2-ethylhexyl) phthalate if flexible PVC is used, or the formulation is transferred to polyolefin bags to avoid plasticizer leaching into the aqueous solution; published data for this specific container compatibility is limited, so extractables and leachables testing is mandated under ICH Q3D and the container manufacturer’s drug master file. The admixture is filtered through an in-line 0.22 µm filter during administration, and the infusion duration is controlled to avoid excessive light exposure; amber overwrapping is applied to protect the dissolved API from photolytic degradation. Particulate matter in the diluted admixture is checked against Ph. Eur. 2.9.19 for sub-visible particles and Ph. Eur. 2.9.20 for visible particles; osmolality is measured with a freezing-point osmometer under Ph. Eur. 2.2.35, and the diluted solution is expected to remain within the accepted tonicity range for peripheral venous administration. The terminal product is a ready-to-administer intravenous infusion for hospital use; the critical process controls are aseptic transfer volume accuracy, needle-free port compatibility and in-line filtration pressure rise, with pressure exceeding 0.8 bar indicating filter blockage from undissolved particulate or precipitant. No terminal sterilization step exists at the point of admixture; therefore, the entire process is governed by hospital pharmacy USP <797> compounding standards or equivalent national standards where applicable, while the industrial concentrate remains subject to ICH Q3D limits and EU GMP Annex 1 for the original sterile manufacturing step.